Abstract
背景与目的非小细胞肺癌(non-small cell lung cancer, NSCLC)脑转移患者接受一代表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor-tyrosine kinase inhibitors, EGFR-TKIs)的生存数据及影响因素未完全阐明。本研究对存在脑转移的NSCLC患者的生存数据进行分析,以期为指导临床实践提供一定的研究证据。方法回顾性收集上海交通大学附属胸科医院2012年-2013年确诊肺癌脑转移并接受一代EGFRTKIs治疗的病例。采用Kaplan-Meier单因素、Cox多因素分析方法,探讨NSCLC脑转移患者接受EGFR-TKIs的生存情况及影响因素。结果总体人群中位无进展生存时间(progression-free survival, PFS)为10.0个月(95%CI: 8.3-11.7),中位生存时间(overall survival, OS)为28.0个月(95%CI: 22.9-33.1)。病理组织类型、肿瘤分化程度分别是患者接受EGFR-TKIs后PFS、OS的独立影响因素(P分别为0.001、0.050)。结论NSCLC脑转移患者接受一代EGFR-TKIs具有良好的疗效,腺癌亚型患者的PFS长于非腺癌患者,其他肿瘤分化程度患者的OS长于肿瘤低分化患者。
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.